Revvity Bundle
Who owns Revvity?
Revvity, Inc. emerged from a significant split of PerkinElmer, Inc. in 2022-2023. This strategic realignment saw its life sciences and diagnostics businesses retain the public trading under the new name Revvity.
The company's name change, reflected in its NYSE stock symbol change from PKI to RVTY on May 16, 2023, signifies a focused approach on its core health science solutions.
Who owns Revvity Company?
Who Founded Revvity?
Revvity, Inc. emerged as a distinct entity through a spin-off, meaning it doesn't have traditional founders like a startup. Its origins are tied to PerkinElmer, Inc., established in 1937 by Richard Scott Perkin and Charles Elmer. The initial capital for the partnership, formed on April 19, 1937, was $15,000 from Perkin and $5,000 from Elmer.
| Key Figure | Role | Involvement Period |
|---|---|---|
| Richard Scott Perkin | Co-Founder, President, CEO, Chairman | 1937 - 1969 |
| Charles Elmer | Co-Founder | 1937 - 1954 |
Founding Partnership
The company's roots trace back to the 1937 partnership between Richard Scott Perkin and Charles Elmer. Their initial capital contributions were $15,000 and $5,000, respectively.
Early Incorporation
The firm was formally incorporated on December 13, 1939. This marked a crucial step in its establishment as a formal business entity.
Transition to Public Trading
Following Charles Elmer's passing in 1954, the company's shares began trading over the counter. This was a precursor to its listing on the New York Stock Exchange on December 13, 1960.
Founder's Leadership
Richard Perkin played a pivotal role, serving as president and CEO until June 1961 and continuing as chairman until his death in 1969. His leadership guided the company through significant early growth.
Early Ownership Structure
While specific details on early equity splits or angel investors are not extensively documented, the transition to public trading signaled a move away from a closely held ownership model.
Legacy of PerkinElmer
Revvity's foundational legacy is directly linked to PerkinElmer, Inc., highlighting a continuous history of innovation and market presence dating back to 1937.
The early ownership of the company that would eventually become Revvity was characterized by the direct involvement of its founders, Richard Scott Perkin and Charles Elmer. Their initial capital investment laid the groundwork for the business, which was formally incorporated in 1939. After Charles Elmer's death in 1954, the company's shares became available through over-the-counter trading, a significant step towards broader ownership. Richard Perkin continued to steer the company as its leader until 1969. This period marked a transition from a founder-controlled entity to a publicly traded company, influencing its subsequent Target Market of Revvity and overall ownership structure.
Key Milestones in Early Ownership
The evolution of ownership from its founding to public trading involved several critical junctures.
- Founding of PerkinElmer, Inc. in 1937 by Richard Scott Perkin and Charles Elmer.
- Initial capital contribution of $15,000 by Richard Perkin and $5,000 by Charles Elmer.
- Formal incorporation of the company on December 13, 1939.
- Shares began trading over the counter after Charles Elmer's passing in 1954.
- Listing on the New York Stock Exchange on December 13, 1960.
- Richard Perkin's continued leadership as chairman until his death in 1969.
Revvity SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Revvity’s Ownership Changed Over Time?
Revvity, Inc.'s ownership journey is deeply intertwined with its former identity as PerkinElmer. A significant shift occurred in 2022 with the divestiture of certain business segments, leading to the rebranding and continued public trading of its life sciences and diagnostics operations under the new name Revvity in May 2023.
| Shareholder Type | Percentage of Ownership | Number of Shares |
|---|---|---|
| Institutional Investors | 97.4% | 113,081,382 |
| General Public | 2.02% | 2,347,510 |
| Insiders | 0.43% | 499,531 |
| State/Government | 0.124% | 144,157 |
The ownership structure of Revvity, Inc. as of August 2025 is heavily concentrated among institutional investors, who hold the vast majority of the company's shares. This significant institutional backing underscores the company's status as a publicly traded entity and influences its strategic direction and corporate governance.
Major Revvity Shareholders
Institutional investors are the dominant force in Revvity's ownership, collectively managing a substantial portion of the company's stock. T. Rowe Price Investment Management leads this group, indicating a strong conviction in Revvity's market position and future prospects.
- T. Rowe Price Investment Management, Inc. holds 19.40% of shares.
- Vanguard Group Inc is another significant holder with 12.39%.
- BlackRock, Inc. possesses 7.54% of the outstanding shares.
- Other key stakeholders include Price T Rowe Associates Inc /md/, Janus Henderson Group Plc, EdgePoint Investment Group Inc., and State Street Corp.
- The company's market capitalization reached $10.64 billion USD as of August 20, 2025.
Understanding the Revvity ownership structure is crucial for assessing its stability and strategic direction. The substantial stake held by institutional investors, such as T. Rowe Price and Vanguard, suggests a focus on long-term value creation. These major shareholders often engage actively with management, influencing decisions related to the Growth Strategy of Revvity and overall corporate performance. The transition from PerkinElmer to Revvity marked a strategic realignment, and the current ownership reflects a focused approach on its core life sciences and diagnostics businesses.
Revvity PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Revvity’s Board?
Revvity, Inc.'s governance is led by its Board of Directors, featuring key figures such as Dr. Prahlad R. Singh as President and CEO, and Alexis P. Michas serving as Non-Executive Chairman. The board includes several senior executives responsible for commercial, financial, and operational aspects of the company.
| Board Member | Position | Affiliation/Role |
| Dr. Prahlad R. Singh | President and Chief Executive Officer | Executive Leadership |
| Alexis P. Michas | Non-Executive Chairman of the Board | Founding Partner of Juniper Investment Company |
| Miriame Victor | Senior Vice President and Chief Commercial Officer | Executive Leadership |
| Maxwell Krakowiak | Senior Vice President and Chief Financial Officer | Executive Leadership |
| Anita Gonzales | Vice President and Controller | Executive Leadership |
| Tajinder Vohra | Senior Vice President, Global Operations | Executive Leadership |
| Joel S. Goldberg | Senior Vice President, Administration, General Counsel and Secretary | Executive Leadership |
As a publicly traded entity on the NYSE, Revvity operates under a standard one-share-one-vote structure for its common stock, indicating that voting power is generally aligned with share ownership. The overwhelming majority of Revvity's shares, approximately 97.4%, are held by institutional investors, granting these entities significant collective voting power. Alexis P. Michas, as the largest individual shareholder, holds 701,878 shares, representing 0.60% of the company's stock, which positions him as a notable individual stakeholder. There have been no significant public reports of proxy contests or activist campaigns influencing the company's strategic direction recently.
Understanding Revvity's Ownership Structure
Revvity's ownership is predominantly held by institutional investors, reflecting broad market confidence. The company's public trading status on the NYSE suggests a transparent voting mechanism.
- Institutional investors control approximately 97.4% of Revvity shares.
- The standard one-share-one-vote principle applies to common stock.
- Alexis P. Michas is the largest individual shareholder with 0.60% ownership.
- No major activist investor campaigns have been publicly reported.
- Understanding Marketing Strategy of Revvity can provide further context on company operations.
Revvity Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Revvity’s Ownership Landscape?
Revvity's ownership profile has undergone significant shifts in recent years, primarily due to a strategic restructuring. The company's focus has sharpened on life sciences and diagnostics following a major spin-off event.
| Event | Year | Details |
|---|---|---|
| Spin-off from PerkinElmer | 2022-2023 | Divestiture of applied, food, and enterprise services businesses for $2.45 billion to New Mountain Capital. |
| Share Repurchase Program Authorization | November 2024 | New $1 billion program authorized, replacing a prior one from May 2023. |
The company's strategic transformation, including the spin-off of its applied, food, and enterprise services businesses for $2.45 billion to New Mountain Capital in 2022, has significantly reshaped its ownership landscape. This move allowed Revvity to concentrate on the high-growth life sciences and diagnostics sectors. Leadership stability is evident with Dr. Prahlad Singh continuing as President and CEO, a key factor in navigating the post-spin-off environment. Revvity anticipates a 3%-5% organic growth rate for 2025, bolstered by increased spending in life sciences consumables, though the high-ticket life science instrumentation market faces ongoing challenges. The company has also updated its full-year 2025 revenue guidance to a range of $2.84 billion to $2.88 billion, with adjusted EPS projected between $4.85 and $4.95.
Shareholder Activity
As of August 5, 2025, Revvity had repurchased 6,091,416 shares, totaling $627.06 million under its latest program. This represents 5.07% of the announced buyback authorization.
Financial Outlook
Revvity has raised its full-year 2025 revenue guidance to between $2.84 billion and $2.88 billion. Adjusted EPS is expected to be in the range of $4.85 to $4.95.
Market Focus
The company's strategic direction emphasizes growth in life sciences and diagnostics. This focus is supported by an anticipated recovery in pharma biotech spending for life sciences consumables.
Leadership and Stability
Dr. Prahlad Singh continues to lead Revvity as President and CEO, providing continuity. This leadership stability is crucial for executing the company's strategic objectives and understanding Mission, Vision & Core Values of Revvity.
Revvity Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Revvity Company?
- What is Competitive Landscape of Revvity Company?
- What is Growth Strategy and Future Prospects of Revvity Company?
- How Does Revvity Company Work?
- What is Sales and Marketing Strategy of Revvity Company?
- What are Mission Vision & Core Values of Revvity Company?
- What is Customer Demographics and Target Market of Revvity Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.